CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the following upcoming conferences:
- H.C. Wainwright 22nd Annual Global Investment Conference, on September 14, 2020, at 2:00 p.m. ET
- Cantor Virtual Global Healthcare Conference, on September 15, 2020, at 4:40 p.m. ET
Live audio webcasts of these presentations will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com. Replays will also be available on Axcella’s website for 30 days following the presentations.
Internet Posting of Information
Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.
Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence. Additional muscle- and blood-related programs are in earlier-stage development. For more information, please visit www.axcellahealth.com.